Skip to main content
OpenTrials
Active, Not Recruiting

NCT Number: NCT05615038

A Comparison of Contact Aspiration Versus Stent Retriever for Acute Basilar Artery Occlusion

Compare the effectiveness and safety of contact aspiration (CA) and stent retriever (SR) in acute ischemic stroke patients with basilar artery occlusion.

Active, Not Recruiting

This study is active but is not currently recruiting participants.

Notify Me

Key information

Conditions

Basilar Artery Occlusion Endovascular Treatment

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

The First Affiliated Hospital of Anhui Medical University, Hefei, Anhui, China

Loading trial locations.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age≥18 years;
  • Acute basilar artery occlusion confirmed by CTA/MRA/DSA;
  • Last known well to puncture time≤24 hours;
  • pc-ASPECTS score≥6 points;
  • Baseline NIHSS score≥10 points;
  • Consent to endovascular treatment;
  • Informed consent signed.

Clinical Exclusion Criteria:

  • Baseline mRS≥3 points;
  • Known or suspected severe basilar artery stenosis (>70%) or chronic occlusion based on history, imaging, or clinical manifestations;
  • Refractory hypertension that is difficult to be controlled by drugs (defined as persistent systolic blood pressure >185 mmHg or diastolic blood pressure >110 mmHg)
  • Genetic or acquired hemorrhagic tendency, coagulation factor deficiency or on anticoagulant therapy and International Normalized Ratio (INR) > 3.0;
  • Laboratory tests: baseline blood glucose <50mg/dl (2.8mmol/L) or >400mg/dl (22.2mmol/L); Baseline platelet count <50×109/L;
  • Known severe allergy (more severe than skin rash) to contrast agents uncontrolled by medications;
  • Females who are pregnant, or those of childbearing, potential with positive urine or serum beta Human Chorionic Gonadotropin test;
  • Other circumstances that the investigator considers inappropriate for participation in the trial or that may pose significant risks to patients (such as inability to understand and/or follow the study procedures and/or follow up due to mental disorders, cognitive or emotional disorders).

Imaging Exclusion Criteria:

  • CT or MR evidence of acute intracranial hemorrhage (the presence of microbleeds on MRI is allowed);
  • Midline shift or herniation, mass effect with effacement of the ventricles;
  • Complete cerebellar infarct on CT or MRI with significant mass effect and compression of the 4-th ventricle;
  • Complete bilateral thalamic infarction on CT or MRI;
  • Inability to endovascular treatment due to Excessive tortuosity, variation, or dissection of the artery;
  • Subjects with occlusions in both intracranial vertebral arteries;
  • Subjects with occlusions in both anterior and posterior circulation;
  • Evidence of intracranial tumor (except small meningioma).

Treatment and study plan

Contact aspiration Thrombectomy

Procedure

Contant aspiration is an approach that utilizes the advantages of large-bore aspiration catheters that can be easily tracked and introduced into the cerebral circulation to directly remove the thrombus via negative pressure aspiration.

Stent retriever thrombectomy

Procedure

Stent retriever thrombetomy is an approach that utilize sself-expandable stent for thrombectomy. The stent retriever is expanded to capture the thrombus, which immediately may restore blood flow.

Primary outcomes

  1. Rate of first pass effect (FPE)

    Time frame: 24 hours

    [The definition of FPE: 1) single pass/use of the device; 2)recanalization of the large vessel occlusion to eTICI 2C/3;3) no use of rescue therapy.]

Secondary outcomes

  1. Rate of complete reperfusion (eTICI 3) after first-line thrombectomy strategy and at the end of endovascular procedure

    Time frame: 24 hours

    eTICI： grade 0: no perfusion noted (0% reperfusion) grade 1: reduction in thrombus but without any resultant filling of distal arterial branches grade 2 grade 2a: reperfusion of 1-49% of the territory grade 2b50: reperfusion of 50-66% of the territory grade 2b67: reperfusion of 67-89% of the territory grade 2c: extensive reperfusion of 90-99% of the territory grade 3: complete or full reperfusion (100% reperfusion)

  2. Rate of near to complete reperfusion (eTICI 2c/3) after first-line thrombectomy strategy and at the end of endovascular procedure

    Time frame: 24 hours

    eTICI： grade 0: no perfusion noted (0% reperfusion) grade 1: reduction in thrombus but without any resultant filling of distal arterial branches grade 2 grade 2a: reperfusion of 1-49% of the territory grade 2b50: reperfusion of 50-66% of the territory grade 2b67: reperfusion of 67-89% of the territory grade 2c: extensive reperfusion of 90-99% of the territory grade 3: complete or full reperfusion (100% reperfusion)

  3. Rate of successful reperfusion (eTICI 2b/2c/3) after first-line thrombectomy strategy and at the end of endovascular procedure

    Time frame: 24 hours

    eTICI： grade 0: no perfusion noted (0% reperfusion) grade 1: reduction in thrombus but without any resultant filling of distal arterial branches grade 2 grade 2a: reperfusion of 1-49% of the territory grade 2b50: reperfusion of 50-66% of the territory grade 2b67: reperfusion of 67-89% of the territory grade 2c: extensive reperfusion of 90-99% of the territory grade 3: complete or full reperfusion (100% reperfusion)

  4. Rate of Arterial Occlusive Lesion (AOL) recanalization score 3 after first-line thrombectomy strategy and at the end of endovascular procedure

    Time frame: 24 hours

    AOL recanalization score is evaluated between 0 to 3:

    0 indicates no recanalization of the primary occlusive lesion;

    • indicates incomplete or partial recanalization of the primary occlusive lesion with no distal flow;
    • indicates incomplete or partial recanalization of the primary occlusive lesion with any distal flow;
    • indicates complete recanalization of the primary occlusive with any distal flow.

  5. Groin puncture time to successful reperfusion time (min)

    Time frame: 24 hours

    evaluated in minutes

  6. The difference of NIHSS score between 24-hour and baseline

    Time frame: 24 hours

    NIHSS (National Institutes of Health Stroke Scale) score is evaluated between 0-42 0 is normal and 42 maximal gravity

  7. Modified Rankin Score (mRS) at 90±14 days (shift analysis)

    Time frame: 90 days

    mRS is evaluated between 0 to 6. A score of 0 indicates that there is no disability and a score of 6 indicates death.

  8. Rate of mRS 0-1 at at 90±14 days

    Time frame: 90 days

    mRS is evaluated between 0 to 6. A score of 0 indicates that there is no disability and a score of 6 indicates death.

  9. Rate of mRS 0-2 at at 90±14 days

    Time frame: 90 days

    mRS is evaluated between 0 to 6. A score of 0 indicates that there is no disability and a score of 6 indicates death.

  10. Rate of mRS 0-3 at at 90±14 days

    Time frame: 90 days

    mRS is evaluated between 0 to 6. A score of 0 indicates that there is no disability and a score of 6 indicates death.

  11. Quality of life at 90±14 days assessed by EuroQol 5D-5L scale

    Time frame: 90 days

    EuroQol 5D-5L comprises five dimensions: mobility, self-care, usual activities, pain/discomfort and anxiety/depression. Each dimension has 5 levels: no problems, slight problems, moderate problems, severe problems and extreme problems. The patient is asked to indicate his/her health state by ticking the box next to the most appropriate statement in each of the five dimensions.

    This decision results in a 1-digit number that expresses the level selected for that dimension. The digits for the five dimensions can be combined into a 5-digit number that describes the patient's health state.

  12. Rate of symptomatic intracranial hemorrhage within 48 hours (according to Heidelberg Bleeding Classification)

    Time frame: 48 hours

    Heidelberg Bleeding Classification:

    • Hemorrhagic transformation of infarcted brain tissue 1a HI1 Scattered small petechiae, no mass effect 1b HI2 Confluent petechiae, no mass effect 1c PH1 Hematoma within infarcted tissue, occupying <30%, no substantive mass effect 2 Intracerebral hemorrhage within and beyond infarcted brain tissue PH2 Hematoma occupying 30% or more of the infarcted tissue, with obvious mass effect 3 Intracerebral hemorrhage outside the infarcted brain tissue or intracranial-extracerebral hemorrhage 3a Parenchymal hematoma remote from infarcted brain tissue 3b Intraventricular hemorrhage 3c Subarachnoid hemorrhage 3d Subdural hemorrhage

  13. Rate of any intracranial hemorrhage within 48 hours (according to Heidelberg Bleeding Classification)

    Time frame: 48 hours

    Heidelberg Bleeding Classification:

    • Hemorrhagic transformation of infarcted brain tissue 1a HI1 Scattered small petechiae, no mass effect 1b HI2 Confluent petechiae, no mass effect 1c PH1 Hematoma within infarcted tissue, occupying <30%, no substantive mass effect 2 Intracerebral hemorrhage within and beyond infarcted brain tissue PH2 Hematoma occupying 30% or more of the infarcted tissue, with obvious mass effect 3 Intracerebral hemorrhage outside the infarcted brain tissue or intracranial-extracerebral hemorrhage 3a Parenchymal hematoma remote from infarcted brain tissue 3b Intraventricular hemorrhage 3c Subarachnoid hemorrhage 3d Subdural hemorrhage

  14. Rate of procedure-related complications, included arterial dissection, embolization in a new territory, arterial perforation and subarachnoid haemorrhage

    Time frame: 24 hours

  15. All cause of mortality at 90±14 days

    Time frame: 90 days

Sponsors and collaborators

Lead sponsor

Beijing Tiantan Hospital

Other

Registry information

Official study title

A Comparison of Contact Aspiration Versus Stent Retriever for Acute Basilar Artery Occlusion: A Multicentre, Prospective, Open-label, Blind Endpoint, Randomized Controlled Trial

Acronym: ANGEL-COAST

Important dates

Study start
2022
Primary completion
2025
Study completion
2025
First posted
Nov 14, 2022
Registry last updated
Apr 27, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.